Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen

Sanofi plans to buy Vigil Neuroscience, a drugmaker advancing TREM2 agonism programs that derive from Amgen. The French pharma will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap ...